NCT00917384 · BASELINE
Baseline characteristics
Results reported by the registry submitting party. Population, time horizon, units and missing values must be read together.
- denoms
- counts
- group Id
- BG000
- value
- 238
- group Id
- BG001
- value
- 117
- group Id
- BG002
- value
- 355
- units
- Participants
- groups
- description
- Participants received IMC-1121B (ramucirumab), administered via intravenous infusion every 2 weeks at a dose of 8 milligrams/kilogram (mg/kg), plus best supportive care (BSC) as determined by the investigator(s). Treatment continued until there was evidence of progressive disease (PD), the development of unacceptable toxicity, protocol noncompliance, or withdrawal of consent.
- id
- BG000
- title
- IMC-1121B (Ramucirumab)
- description
- Participants received placebo by intravenous infusion every 2 weeks plus best supportive care as determined appropriate by the investigator(s). Because investigators and ancillary medical personnel were blinded as to assignment to active therapy versus placebo, the volume of placebo administered was calculated as if it were active product with a dose of 8 mg/kg. Treatment continued until there was evidence of PD, the development of unacceptable toxicity, protocol noncompliance, or withdrawal of consent.
- id
- BG001
- title
- Placebo
- description
- Total of all reporting groups
- id
- BG002
- title
- Total
- measures
- classes
- categories
- measurements
- group Id
- BG000
- lower Limit
- 30
- upper Limit
- 86
- value
- 60.0
- group Id
- BG001
- lower Limit
- 24
- upper Limit
- 87
- value
- 60.0
- group Id
- BG002
- lower Limit
- 24
- upper Limit
- 87
- value
- 60.0
- dispersion Type
- FULL_RANGE
- param Type
- MEDIAN
- title
- Age, Continuous
- unit Of Measure
- years
- classes
- categories
- measurements
- group Id
- BG000
- value
- 69
- group Id
- BG001
- value
- 38
- group Id
- BG002
- value
- 107
- title
- Female
- measurements
- group Id
- BG000
- value
- 169
- group Id
- BG001
- value
- 79
- group Id
- BG002
- value
- 248
- title
- Male
- param Type
- COUNT_OF_PARTICIPANTS
- title
- Sex: Female, Male
- unit Of Measure
- Participants
- classes
- categories
- measurements
- group Id
- BG000
- value
- 41
- group Id
- BG001
- value
- 19
- group Id
- BG002
- value
- 60
- title
- Hispanic or Latino
- measurements
- group Id
- BG000
- value
- 197
- group Id
- BG001
- value
- 98
- group Id
- BG002
- value
- 295
- title
- Not Hispanic or Latino
- measurements
- group Id
- BG000
- value
- 0
- group Id
- BG001
- value
- 0
- group Id
- BG002
- value
- 0
- title
- Unknown or Not Reported
- param Type
- COUNT_OF_PARTICIPANTS
- title
- Ethnicity (NIH/OMB)
- unit Of Measure
- Participants
- classes
- categories
- measurements
- group Id
- BG000
- value
- 4
- group Id
- BG001
- value
- 2
- group Id
- BG002
- value
- 6
- title
- Argentina
- categories
- measurements
- group Id
- BG000
- value
- 8
- group Id
- BG001
- value
- 4
- group Id
- BG002
- value
- 12
- title
- Australia
- categories
- measurements
- group Id
- BG000
- value
- 1
- group Id
- BG001
- value
- 3
- group Id
- BG002
- value
- 4
- title
- Bosnia and Herzegovina
- categories
- measurements
- group Id
- BG000
- value
- 24
- group Id
- BG001
- value
- 14
- group Id
- BG002
- value
- 38
- title
- Brazil
- categories
- measurements
- group Id
- BG000
- value
- 8
- group Id
- BG001
- value
- 2
- group Id
- BG002
- value
- 10
- title
- Canada
- categories
- measurements
- group Id
- BG000
- value
- 1
- group Id
- BG001
- value
- 1
- group Id
- BG002
- value
- 2
- title
- Chile
- categories
- measurements
- group Id
- BG000
- value
- 2
- group Id
- BG001
- value
- 1
- group Id
- BG002
- value
- 3
- title
- Colombia
- categories
- measurements
- group Id
- BG000
- value
- 24
- group Id
- BG001
- value
- 13
- group Id
- BG002
- value
- 37
- title
- Czech Republic
- categories
- measurements
- group Id
- BG000
- value
- 1
- group Id
- BG001
- value
- 0
- group Id
- BG002
- value
- 1
- title
- Egypt
- categories
- measurements
- group Id
- BG000
- value
- 12
- group Id
- BG001
- value
- 4
- group Id
- BG002
- value
- 16
- title
- Spain
- categories
- measurements
- group Id
- BG000
- value
- 13
- group Id
- BG001
- value
- 4
- group Id
- BG002
- value
- 17
- title
- United Kingdom
- categories
- measurements
- group Id
- BG000
- value
- 6
- group Id
- BG001
- value
- 2
- group Id
- BG002
- value
- 8
- title
- Guatemala
- param Type
- NUMBER
- title
- Region of Enrollment
- unit Of Measure
- participants
- classes
- categories
- measurements
- group Id
- BG000
- value
- 181
- group Id
- BG001
- value
- 91
- group Id
- BG002
- value
- 272
- title
- White
- categories
- measurements
- group Id
- BG000
- value
- 39
- group Id
- BG001
- value
- 17
- group Id
- BG002
- value
- 56
- title
- Asian
- categories
- measurements
- group Id
- BG000
- value
- 4
- group Id
- BG001
- value
- 2
- group Id
- BG002
- value
- 6
- title
- Black
- categories
- measurements
- group Id
- BG000
- value
- 14
- group Id
- BG001
- value
- 7
- group Id
- BG002
- value
- 21
- title
- Other
- param Type
- NUMBER
- title
- Race
- unit Of Measure
- participants
- population Description
- All randomized participants.
Complete source fields
- denoms
- counts
- group Id
- BG000
- value
- 238
- group Id
- BG001
- value
- 117
- group Id
- BG002
- value
- 355
- units
- Participants
- groups
- description
- Participants received IMC-1121B (ramucirumab), administered via intravenous infusion every 2 weeks at a dose of 8 milligrams/kilogram (mg/kg), plus best supportive care (BSC) as determined by the investigator(s). Treatment continued until there was evidence of progressive disease (PD), the development of unacceptable toxicity, protocol noncompliance, or withdrawal of consent.
- id
- BG000
- title
- IMC-1121B (Ramucirumab)
- description
- Participants received placebo by intravenous infusion every 2 weeks plus best supportive care as determined appropriate by the investigator(s). Because investigators and ancillary medical personnel were blinded as to assignment to active therapy versus placebo, the volume of placebo administered was calculated as if it were active product with a dose of 8 mg/kg. Treatment continued until there was evidence of PD, the development of unacceptable toxicity, protocol noncompliance, or withdrawal of consent.
- id
- BG001
- title
- Placebo
- description
- Total of all reporting groups
- id
- BG002
- title
- Total
- measures
- classes
- categories
- measurements
- group Id
- BG000
- lower Limit
- 30
- upper Limit
- 86
- value
- 60.0
- group Id
- BG001
- lower Limit
- 24
- upper Limit
- 87
- value
- 60.0
- group Id
- BG002
- lower Limit
- 24
- upper Limit
- 87
- value
- 60.0
- dispersion Type
- FULL_RANGE
- param Type
- MEDIAN
- title
- Age, Continuous
- unit Of Measure
- years
- classes
- categories
- measurements
- group Id
- BG000
- value
- 69
- group Id
- BG001
- value
- 38
- group Id
- BG002
- value
- 107
- title
- Female
- measurements
- group Id
- BG000
- value
- 169
- group Id
- BG001
- value
- 79
- group Id
- BG002
- value
- 248
- title
- Male
- param Type
- COUNT_OF_PARTICIPANTS
- title
- Sex: Female, Male
- unit Of Measure
- Participants
- classes
- categories
- measurements
- group Id
- BG000
- value
- 41
- group Id
- BG001
- value
- 19
- group Id
- BG002
- value
- 60
- title
- Hispanic or Latino
- measurements
- group Id
- BG000
- value
- 197
- group Id
- BG001
- value
- 98
- group Id
- BG002
- value
- 295
- title
- Not Hispanic or Latino
- measurements
- group Id
- BG000
- value
- 0
- group Id
- BG001
- value
- 0
- group Id
- BG002
- value
- 0
- title
- Unknown or Not Reported
- param Type
- COUNT_OF_PARTICIPANTS
- title
- Ethnicity (NIH/OMB)
- unit Of Measure
- Participants
- classes
- categories
- measurements
- group Id
- BG000
- value
- 4
- group Id
- BG001
- value
- 2
- group Id
- BG002
- value
- 6
- title
- Argentina
- categories
- measurements
- group Id
- BG000
- value
- 8
- group Id
- BG001
- value
- 4
- group Id
- BG002
- value
- 12
- title
- Australia
- categories
- measurements
- group Id
- BG000
- value
- 1
- group Id
- BG001
- value
- 3
- group Id
- BG002
- value
- 4
- title
- Bosnia and Herzegovina
- categories
- measurements
- group Id
- BG000
- value
- 24
- group Id
- BG001
- value
- 14
- group Id
- BG002
- value
- 38
- title
- Brazil
- categories
- measurements
- group Id
- BG000
- value
- 8
- group Id
- BG001
- value
- 2
- group Id
- BG002
- value
- 10
- title
- Canada
- categories
- measurements
- group Id
- BG000
- value
- 1
- group Id
- BG001
- value
- 1
- group Id
- BG002
- value
- 2
- title
- Chile
- categories
- measurements
- group Id
- BG000
- value
- 2
- group Id
- BG001
- value
- 1
- group Id
- BG002
- value
- 3
- title
- Colombia
- categories
- measurements
- group Id
- BG000
- value
- 24
- group Id
- BG001
- value
- 13
- group Id
- BG002
- value
- 37
- title
- Czech Republic
- categories
- measurements
- group Id
- BG000
- value
- 1
- group Id
- BG001
- value
- 0
- group Id
- BG002
- value
- 1
- title
- Egypt
- categories
- measurements
- group Id
- BG000
- value
- 12
- group Id
- BG001
- value
- 4
- group Id
- BG002
- value
- 16
- title
- Spain
- categories
- measurements
- group Id
- BG000
- value
- 13
- group Id
- BG001
- value
- 4
- group Id
- BG002
- value
- 17
- title
- United Kingdom
- categories
- measurements
- group Id
- BG000
- value
- 6
- group Id
- BG001
- value
- 2
- group Id
- BG002
- value
- 8
- title
- Guatemala
- param Type
- NUMBER
- title
- Region of Enrollment
- unit Of Measure
- participants
- classes
- categories
- measurements
- group Id
- BG000
- value
- 181
- group Id
- BG001
- value
- 91
- group Id
- BG002
- value
- 272
- title
- White
- categories
- measurements
- group Id
- BG000
- value
- 39
- group Id
- BG001
- value
- 17
- group Id
- BG002
- value
- 56
- title
- Asian
- categories
- measurements
- group Id
- BG000
- value
- 4
- group Id
- BG001
- value
- 2
- group Id
- BG002
- value
- 6
- title
- Black
- categories
- measurements
- group Id
- BG000
- value
- 14
- group Id
- BG001
- value
- 7
- group Id
- BG002
- value
- 21
- title
- Other
- param Type
- NUMBER
- title
- Race
- unit Of Measure
- participants
- population Description
- All randomized participants.
Download exact source JSON → · Snapshot ctgov-results-191f4516d4760045304b24a0
Preserved source evidence · Not medical advice
Triangle